Clinical trial results:
An open-label, multi-national, multi-center, single-arm, uncontrolled, longterm extension study of orally administered riociguat in patients with symptomatic pulmonary arterial hypertension (PAH) who received riociguat in a Bayer clinical trial

Summary

EudraCT number	2016-000501-36
Trial protocol	FR IT
Global end of trial date	15 September 2025

Results information

Result version number	v1 (current)
This version publication date	27 February 2026
First version publication date	27 February 2026

Trial information

Trial identification

Sponsor protocol code	BAY63-2521/18694

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02759419
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bayer AG
Sponsor organisation address	Kaiser Wilhelm Allee, Leverkusen, Germany, D-51368
Public contact	Therapeutic Area Head, Bayer AG, +49 30 300139003, clinical-trials-contact@bayer.com
Scientific contact	Therapeutic Area Head, Bayer AG, +49 30 300139003, clinical-trials-contact@bayer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 October 2025
Is this the analysis of the primary completion data?	Yes
Primary completion date	15 September 2025
Global end of trial reached?	Yes
Global end of trial date	15 September 2025
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To provide riociguat therapy to eligible patients with PAH originating from the Bayer-sponsored trials 12935 PATENT-2 or 16719 RESPITE who are currently or recently treated in these trials until lack of patient benefit as assessed by investigator, or commercial availability and reimbursement.

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and the International Council for Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent was read by and explained to all the subjects. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	16 June 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	France: 7
Country: Number of subjects enrolled	Korea, Republic of: 11
Worldwide total number of subjects	18
EEA total number of subjects	7

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	15
From 65 to 84 years	3
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was conducted at 9 study centers in 2 countries (5 in France and 4 in South Korea) between 16 June 2016 (first participant first visit)
consent) and 15 September 2025 (last participant last visit).

Pre-assignment

Screening details:

A total of 18 participants were enrolled and no participant failed screening.
All 18 participants received study intervention. 12 Participants did not complete the treatment phase.

Period 1

Period 1 title	overall (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Riociguat (BAY 63-2521)

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Riociguat (BAY 63-2521)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

0.5 to 2.5 mg in 0.5 mg increments (according to individually adapted optimal dose) administered three times daily

Number of subjects in period 1	Riociguat (BAY 63-2521)
Started	18
Completed	6
Not completed	12
Consent withdrawn by subject	1
Physician decision	5
Adverse event, non-fatal	1
Death	4
Lost to follow-up	1

Baseline characteristics

Reporting groups	
Reporting group title	Riociguat (BAY 63-2521)

Reporting group description: -

Reporting group values	Riociguat (BAY 63-2521)	Total	
Number of subjects	18	18	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	15	15	
From 65-84 years	3	3	
85 years and over	0	0	
Gender categorical Units: Subjects			
Female	12	12	
Male	6	6	

End points

End points reporting groups

Reporting group title	Riociguat (BAY 63-2521)

Reporting group description: -

Primary: Number of Participants with treatment emergent adverse events (TEAE)s

End point title	Number of Participants with treatment emergent adverse events (TEAE)s[1]

End point description:

End point type	Primary

End point timeframe:

From first intake of study medication until end of study.

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Due to the limited number of patients, statistical analyses included in this study focused on descriptive statistics only.

End point values	Riociguat (BAY 63-2521)			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: Participants				
any TEAE	18			
mild TEAE	3			
moderate TEAE	6			
severe TEAE	9			
any treatment-related TEAE	5			
mild treatment-related TEAE	2			
moderate treatment-related TEAE	2			
severe treatment-related TEAE	1			
any TEAE leading to discontinuation ofintervention	5			
any TEAE leading to modification ofintervention	0			
any TEAE of special interest	0			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse event data were collected after signing the informed consent until 30 days after end of study treatment over a period of approximately five years.

Adverse event reporting additional description:

12 participants (66.7%) reported at least 1 treatment-emergent SAE (cross ref to table) including 4 deaths. None of the tretament emergent SAE/death was assessed as treatment-related.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	28.0

Reporting groups

Reporting group title	Full Analysis Set

Reporting group description:

All 18 participants, who have been included in the study and have received at least one dose of the study treatment.

Serious adverse events	Full Analysis Set		
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 18 (66.67%)		
number of deaths (all causes)	4		
number of deaths resulting from adverse events	4		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm recurrence			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Pancreatic carcinoma			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Bleeding varicose vein			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			

Peritoneal catheter insertion				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Salpingo-oophorectomy bilateral				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
General disorders and administration site conditions				
Pyrexia				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Respiratory, thoracic and mediastinal disorders				
Dyspnoea				
subjects affected / exposed	3 / 18 (16.67%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Pulmonary arterial hypertension				
subjects affected / exposed	3 / 18 (16.67%)			
occurrences causally related to treatment / all	0 / 6			
deaths causally related to treatment / all	0 / 1			
Lung disorder				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cardiac disorders				
Atrial flutter				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cardiac arrest				

subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Palpitations				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Right ventricular failure				
subjects affected / exposed	2 / 18 (11.11%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 1			
Nervous system disorders				
Cognitive disorder				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Dizziness				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Epilepsy				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hepatic encephalopathy				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Ischaemic stroke				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Syncope				

subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Vocal cord paralysis				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Blood and lymphatic system disorders				
Anaemia				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Thrombotic microangiopathy				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Gastrointestinal disorders				
Ascites				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Haematemesis				
subjects affected / exposed	2 / 18 (11.11%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Haemoperitoneum				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Nausea				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Hepatobiliary disorders				

Bile duct stenosis				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Cholangitis				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Hepatic cirrhosis				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Skin and subcutaneous tissue disorders				
Urticaria				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Renal and urinary disorders				
Acute kidney injury				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Proteinuria				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Renal failure				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
Infection				

subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Full Analysis Set		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	18 / 18 (100.00%)		
Vascular disorders			
Bleeding varicose vein			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hypertension			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Hypotension			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Surgical and medical procedures			
Liver transplant			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
General disorders and administration site conditions			
Administration site pain			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Asthenia			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	4		
Chest pain			

subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Fatigue			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Oedema			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Oedema peripheral			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	5		
Pain			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Pyrexia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	2		
Inflammation			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Reproductive system and breast disorders			
Pelvic cyst			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Vaginal haemorrhage			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	2		
Dyspnoea			
subjects affected / exposed	4 / 18 (22.22%)		
occurrences (all)	5		
Epistaxis			

subjects affected / exposed occurrences (all)	3 / 18 (16.67%) 4		
Lung disorder subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 2		
Orthopnoea subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Pulmonary arterial hypertension subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Sleep apnoea syndrome subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Snoring subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Insomnia subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 2		
Product issues Device breakage subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Investigations N-terminal prohormone brain natriuretic peptide increased subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Platelet count decreased			

subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Ligament sprain			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Cardiac disorders			
Arrythmia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Atrial fibrillation			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Right ventricular failure			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	3		
Ventricular tachycardia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Nervous system disorders			
Dizziness			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	6		
Essential tremor			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Headache			
subjects affected / exposed	6 / 18 (33.33%)		
occurrences (all)	7		
Presyncope			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Syncope			

subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	3		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 18 (16.67%)		
occurrences (all)	3		
Thrombocytopenia			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Ear and labyrinth disorders			
Hypoacusis			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Vertigo			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Eye disorders			
Cataract			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Diabetic retinopathy			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Glaucoma			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	2		
Macular degeneration			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Conjunctival oedema			
subjects affected / exposed	1 / 18 (5.56%)		
occurrences (all)	1		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 18 (11.11%)		
occurrences (all)	4		
Abdominal pain upper			

subjects affected / exposed	2 / 18 (11.11%)			
occurrences (all)	2			
Ascites				
subjects affected / exposed	2 / 18 (11.11%)			
occurrences (all)	2			
Constipation				
subjects affected / exposed	2 / 18 (11.11%)			
occurrences (all)	3			
Diarrhoea				
subjects affected / exposed	7 / 18 (38.89%)			
occurrences (all)	11			
Functional gastrointestinal disorder				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	1			
Gastric ulcer				
subjects affected / exposed	2 / 18 (11.11%)			
occurrences (all)	2			
Gastrointestinal haemorrhage				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	1			
Gastrooesophageal reflux disease				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	1			
Haematemesis				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	1			
Haematochezia				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	1			
Melaena				
subjects affected / exposed	2 / 18 (11.11%)			
occurrences (all)	2			
Nausea				
subjects affected / exposed	3 / 18 (16.67%)			
occurrences (all)	3			
Oesophagitis				

subjects affected / exposed occurrences (all) Small intestinal haemorrhage subjects affected / exposed occurrences (all) Tooth disorder subjects affected / exposed occurrences (all) Vomiting subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1 1 / 18 (5.56%) 1 1 / 18 (5.56%) 1 2 / 18 (11.11%) 3		
Hepatobiliary disorders Bile duct stenosis subjects affected / exposed occurrences (all) Cholangitis subjects affected / exposed occurrences (all) Congestive hepatopathy subjects affected / exposed occurrences (all)	 1 / 18 (5.56%) 3 1 / 18 (5.56%) 1 1 / 18 (5.56%) 1		
Skin and subcutaneous tissue disorders Cold sweat subjects affected / exposed occurrences (all) Eczema subjects affected / exposed occurrences (all) Pruritus subjects affected / exposed occurrences (all) Skin reaction subjects affected / exposed occurrences (all)	 1 / 18 (5.56%) 1 1 / 18 (5.56%) 1 2 / 18 (11.11%) 2 1 / 18 (5.56%) 1		
Renal and urinary disorders			

Acute kidney injury subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Chronic kidney disease subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 2		
Urinary incontinence subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 2		
Back pain subjects affected / exposed occurrences (all)	3 / 18 (16.67%) 3		
Coccydynia subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Myalgia subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 2		
Pain in extremity subjects affected / exposed occurrences (all)	3 / 18 (16.67%) 3		
Pain in jaw subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Torticollis subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1		
Infections and infestations			

COVID-19				
subjects affected / exposed	4 / 18 (22.22%)			
occurrences (all)	4			
Cellulitis				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	1			
Ear infection				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	1			
Erysipelas				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	1			
Fungal infection				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	1			
Gastroenteritis				
subjects affected / exposed	2 / 18 (11.11%)			
occurrences (all)	2			
Influenza				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	1			
Nasopharyngitis				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	1			
Otitis externa				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	1			
Pharyngitis				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	1			
Pneumonia				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	1			
Rhinitis				
subjects affected / exposed	1 / 18 (5.56%)			
occurrences (all)	4			

Septic shock subjects affected / exposed occurrences (all) Upper respiratory tract infection subjects affected / exposed occurrences (all) Urinary tract infection subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1 2 / 18 (11.11%) 3 2 / 18 (11.11%) 2		
Metabolism and nutrition disorders Dehydration subjects affected / exposed occurrences (all) Folate deficiency subjects affected / exposed occurrences (all) Gout subjects affected / exposed occurrences (all) Hyperglycaemia subjects affected / exposed occurrences (all) Iron deficiency subjects affected / exposed occurrences (all) Vitamin D deficiency subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1 1 / 18 (5.56%) 1 2 / 18 (11.11%) 2 1 / 18 (5.56%) 1 1 / 18 (5.56%) 1 1 / 18 (5.56%) 1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 August 2016	inclusion of a new exclusion criterion
10 March 2017	Opening of the study for patients from study 18588 (REPLACE)

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported